HMPL-004: Preliminary Phase IIa data

Preliminary data from a double-blind, placebo-controlled, U.S. and Ukrainian Phase IIa trial in 101 patients showed that 1,200 mg/day HMPL-004 missed the primary endpoint of reducing CDAI by >=100 poi...